Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117832213 | 11783221 | 3 | F | 20100408 | 20160809 | 20151127 | 20160816 | EXP | PHHY2012IL029184 | NOVARTIS | 54.38 | YR | M | Y | 76.00000 | KG | 20160816 | CN | COUNTRY NOT SPECIFIED | IL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117832213 | 11783221 | 1 | PS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG EVERY 10 DAYS | 50288 | 21008 | 30 | MG | |||||||
| 117832213 | 11783221 | 2 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG EVERY 10 DAYS | 21008 | 30 | MG | ||||||||
| 117832213 | 11783221 | 3 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, EVERY 10 DAYS | 21008 | 30 | MG | ||||||||
| 117832213 | 11783221 | 4 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, QW | SO276, S0309 | 21008 | 30 | MG | /wk | ||||||
| 117832213 | 11783221 | 5 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, QW | S0321A | 21008 | 30 | MG | /wk |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 117832213 | 11783221 | 1 | Neuroendocrine tumour |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 117832213 | 11783221 | OT |
| 117832213 | 11783221 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 117832213 | 11783221 | Abdominal pain | |
| 117832213 | 11783221 | Back pain | |
| 117832213 | 11783221 | Faecal volume increased | |
| 117832213 | 11783221 | Flatulence | |
| 117832213 | 11783221 | Flushing | |
| 117832213 | 11783221 | Frequent bowel movements | |
| 117832213 | 11783221 | Inappropriate schedule of drug administration | |
| 117832213 | 11783221 | Injection site mass | |
| 117832213 | 11783221 | Injection site pain | |
| 117832213 | 11783221 | Malignant neoplasm progression | |
| 117832213 | 11783221 | Metastases to liver | |
| 117832213 | 11783221 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 117832213 | 11783221 | 1 | 20100408 | 0 | ||
| 117832213 | 11783221 | 2 | 20120402 | 0 | ||
| 117832213 | 11783221 | 3 | 20130317 | 0 | ||
| 117832213 | 11783221 | 4 | 20141014 | 0 |